Estradiol acetate
As of the edition of 20 October 2026, Estradiol acetate is a small molecule: marketed, first approved in 2003 (US); acts on ESR1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2003
- Kind
- Small molecule
- Brand name
- Femring
- First approved
- 20 March 2003 (US)
- Approvals on record
- 5 in 1 region
- Holder of the most recent approval
- AbbVie; 2 holders in all
- Registered trials
- 2, 0 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Estradiol acetate.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ESR1 | Estrogen receptor | P03372 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Warner Chilcott | Later holder and Lead sponsor of trials | 2003 to now |
| AbbVie | Acquired holder | 2016 to now |
| Millicent Manufacturing Pr | Acquired holder | 2026 to now |
| Galen | Originator | 2003 to 2026 |